Motilal Oswal Financial Services Limited

Sun Pharma has delivered a strong beat on FY23 earnings, led by broad-based growth across business segments. We remain positive on Sun Pharma on the back of sustained scale-up in speciality portfolio, robust franchise building in branded generics portfolio, and healthy ANDA pipeline pending approvals Re-iterate BUY. Glimpse the company's performance and key highlights to improve your decision. 📝 Read more: http://ow.ly/93NL50KZr3i🔗 Disclaimer: http://ow.ly/RK0h50KZrgj ⬇️ Download the app now: http://ow.ly/nKgB50KSKKk☑️ Follow us for such informative content. 🔖 Save the post for your future reference. ▶️ Share this post with your friends if you found it informative. #MotilalOswal #CompanySpotlight #SunPharma #SunPharmastock #experttips #chooserightstocks #investmentadvice #stockmarket #stockrecommendations #stockratings #stockanalysis #fundamentalanalysis #technicalanalysis #technicalreserach #marketanalysis #expertadvice #MotilalOswal #CompanySpotlight #SunPharma #SunPharmastock #experttips #chooserightstocks #investmentadvice #stockmarket #stockrecommendations #stockratings #stockanalysis #fundamentalanalysis #technicalanalysis #technicalreserach #marketanalysis #expertadvice